Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

NCT01625286 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Breast Cancer
ER+ve Advanced or Metastatic Breast Cancer

Interventions

DRUG: AZD5363 when combined with weekly paclitaxel.
DRUG: AZD5363 when combined with weekly paclitaxel.
DRUG: AZD5363when combined with weekly paclitaxel.
DRUG: A placebo in combination with weekly paclitaxel.

Sponsor

AstraZeneca